Navigation Links
Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
Date:10/21/2008

CALGARY, Oct. 21 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 7th Annual BIO Investor Forum 2008 on Wednesday, October 29, 2008 at 2:15 p.m. PT. The conference will be held at the Palace Hotel in San Francisco from October 29-31, 2008.

A live audio link to the webcast presentation is available at: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ONC.TO&item_id=1996001, or on the company's website at http://www.oncolyticsbiotech.com. It is recommended that listeners log on 15 minutes in advance of the presentation to register and download any necessary software.

An audio replay will be accessible approximately one hour following the presentation on the Oncolytics website.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

The presentation and webcast times are subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Six Sigma and Social Media: Tools for Reducing Costs, Improving Processes
2. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
3. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
4. Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008
5. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
6. U.S. News Media Group Releases 19th Edition of Americas Best Hospitals
7. VIDEO from Medialink and Med-El: New Technology is Music to Peoples Ears
8. BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media
9. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
10. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
11. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... ... July 13, 2017 , ... ... instruments in Orthopedics, has announced today the completion of a major transaction with ... drive organic and external growth. The alliance fuels In’Tech Medical’s service offerings while ...
(Date:7/13/2017)... Philadelphia, PA (PRWEB) , ... July 13, 2017 ... ... and business acceleration programs at Philadelphia’s University City Science Center, Christopher Laing, MRCVS, ... innovation zone in Austin, Texas. Dr. Laing will become the first Executive ...
(Date:7/12/2017)... ... July 12, 2017 , ... Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the ... reagents used for diagnostic tests, announced today that its initial public offering of 1,178,532 ... from the offering will be $7,071,192. , The shares will begin trading on July ...
(Date:7/12/2017)... Frederick, MD (PRWEB) , ... July 12, 2017 ... ... software solutions provider is pleased to announce the release of FreezerPro® version 7.2. ... registration and aliquoting, and query sample information. For ten years, RURO has been ...
Breaking Biology Technology:
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/18/2017)... April 18, 2017  Socionext Inc., a global expert in SoC-based ... edge server, the M820, which features the company,s hybrid codec technology. ... by Tera Probe, Inc., will be showcased during the upcoming Medtec ... show at the Las Vegas Convention Center ... Click here ...
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
Breaking Biology News(10 mins):